Five species of Ebola virus (EBOV) have been identified, with nucleotide differences of 30–45% between species. Four of these species have been shown to cause Ebola hemorrhagic fever (EHF) in humans and a fifth species (Reston ebolavirus) is capable of causing a similar disease in non-human primates. While examining potential serologic cross-reactivity between EBOV species is important for diagnostic assays as well as putative vaccines, the nature of cross-reactive antibodies following EBOV infection has not been thoroughly characterized. In order to examine cross-reactivity of human serologic responses to EBOV, we developed antigen preparations for all five EBOV species, and compared serologic responses by IgM capture and IgG enzyme-linked immunosorbent assay (ELISA) in groups of convalescent diagnostic sera from outbreaks in Kikwit, Democratic Republic of Congo (n = 24), Gulu, Uganda (n = 20), Bundibugyo, Uganda (n = 33), and the Philippines (n = 18), which represent outbreaks due to four different EBOV species. For groups of samples from Kikwit, Gulu, and Bundibugyo, some limited IgM cross-reactivity was noted between heterologous sera-antigen pairs, however, IgM responses were largely stronger against autologous antigen. In some instances IgG responses were higher to autologous antigen than heterologous antigen, however, in contrast to IgM responses, we observed strong cross-reactive IgG antibody responses to heterologous antigens among all sets of samples. Finally, we examined autologous IgM and IgG antibody levels, relative to time following EHF onset, and observed early peaking and declining IgM antibody levels (by 80 days) and early development and persistence of IgG antibodies among all samples, implying a consistent pattern of antibody kinetics, regardless of EBOV species. Our findings demonstrate limited cross-reactivity of IgM antibodies to EBOV, however, the stronger tendency for cross-reactive IgG antibody responses can largely circumvent limitations in the utility of heterologous antigen for diagnostic assays and may assist in the development of antibody-mediated vaccines to EBOV.
References
[1]
Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, et al. (2010) Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 155: 2083–2103. doi: 10.1007/s00705-010-0814-x
[2]
WHO (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56: 271–293.
[3]
WHO (1978) Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56: 247–270.
[4]
(2001) Outbreak of Ebola hemorrhagic fever Uganda, August 2000–January 2001. MMWR Morb Mortal Wkly Rep 50: 73–77.
[5]
Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, et al. (1999) The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179: Suppl 1S76–86. doi: 10.1086/514306
[6]
Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, et al. (1999) Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 179: Suppl 1S48–53. doi: 10.1086/514285
[7]
Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, et al. (1999) Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues. J Infect Dis 179: Suppl 1S65–75. doi: 10.1086/514290
[8]
Wamala JF, Lukwago L, Malimbo M, Nguku P, Yoti Z, et al. (2010) Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007–2008. Emerg Infect Dis 16: 1087–1092. doi: 10.3201/eid1607.091525
[9]
Macneil A, Farnon EC, Wamala J, Okware S, Cannon DL, et al. (2010) Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda. Emerg Infect Dis 16: 1969–1972. doi: 10.3201/eid1612.100627
Hayes CG, Burans JP, Ksiazek TG, Del Rosario RA, Miranda ME, et al. (1992) Outbreak of fatal illness among captive macaques in the Philippines caused by an Ebola-related filovirus. Am J Trop Med Hyg 46: 664–671.
[12]
Miranda ME, Yoshikawa Y, Manalo DL, Calaor AB, Miranda NL, et al. (2002) Chronological and spatial analysis of the 1996 Ebola Reston virus outbreak in a monkey breeding facility in the Philippines. Exp Anim 51: 173–179. doi: 10.1538/expanim.51.173
[13]
Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325: 204–206. doi: 10.1126/science.1172705
[14]
(1990) Update: Filovirus Infections Among Persons with Occupational Exposure to Nonhuman Primates. MMWR Morb Mortal Wkly Rep 39: 266, 273.
[15]
Miranda ME, White ME, Dayrit MM, Hayes CG, Ksiazek TG, et al. (1991) Seroepidemiological study of filovirus related to Ebola in the Philippines. Lancet 337: 425–426. doi: 10.1016/0140-6736(91)91199-5
[16]
Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4: e1000212. doi: 10.1371/journal.ppat.1000212
[17]
Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, et al. (1999) Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S177–187. doi: 10.1086/514321
[18]
Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5: 423–426. doi: 10.1038/7422
[19]
Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, et al. (2004) Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78: 4330–4341. doi: 10.1128/JVI.78.8.4330-4341.2004
[20]
Onyango CO, Opoka ML, Ksiazek TG, Formenty P, Ahmed A, et al. (2007) Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004. J Infect Dis 196: Suppl 2S193–198. doi: 10.1086/520609
[21]
Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, et al. (1999) Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179: Suppl 1S28–35. doi: 10.1086/514318
[22]
Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, et al. (2000) Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355: 2210–2215. doi: 10.1016/S0140-6736(00)02405-3
[23]
Groseth A, Feldmann H, Strong JE (2007) The ecology of Ebola virus. Trends Microbiol 15: 408–416. doi: 10.1016/j.tim.2007.08.001
[24]
Feldmann H, Geisbert TW doi: 10.3791/4201
[25]
Richman DD, Cleveland PH, McCormick JB, Johnson KM (1983) Antigenic analysis of strains of Ebola virus: identification of two Ebola virus serotypes. J Infect Dis 147: 268–271. doi: 10.1093/infdis/147.2.268
[26]
Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, et al. (1995) Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345: 1271–1274. doi: 10.1016/S0140-6736(95)90925-7
[27]
Ksiazek TG, West CP, Rollin PE, Jahrling PB, Peters CJ (1999) ELISA for the detection of antibodies to Ebola viruses. J Infect Dis 179: Suppl 1S192–198. doi: 10.1086/514313
[28]
Elliott LH, Bauer SP, Perez-Oronoz G, Lloyd ES (1993) Improved specificity of testing methods for filovirus antibodies. J Virol Methods 43: 85–89. doi: 10.1016/0166-0934(93)90092-6
[29]
Brandt WE, Buescher EL, Hetrick FM (1967) Production and characterization of arbovirus antibody in mouse ascitic fluid. Am J Trop Med Hyg 16: 339–347.
[30]
Prehaud C, Hellebrand E, Coudrier D, Volchkov VE, Volchkova VA, et al. (1998) Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections. J Gen Virol 79(Pt 11): 2565–2572.
[31]
Saijo M, Niikura M, Morikawa S, Ksiazek TG, Meyer RF, et al. (2001) Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins. J Clin Microbiol 39: 1–7. doi: 10.1128/JCM.39.1.1-7.2001
[32]
Nakayama E, Yokoyama A, Miyamoto H, Igarashi M, Kishida N, et al. (2010) Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 17: 1723–1728. doi: 10.1128/CVI.00170-10
[33]
Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 6: e1000904. doi: 10.1371/journal.ppat.1000904
[34]
Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, et al. (1999) Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S102–107. doi: 10.1086/514309
[35]
Gonzalez JP, Nakoune E, Slenczka W, Vidal P, Morvan JM (2000) Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect 2: 39–44. doi: 10.1016/S1286-4579(00)00287-2
[36]
Becquart P, Wauquier N, Mahlakoiv T, Nkoghe D, Padilla C, et al. (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 5: e9126. doi: 10.1371/journal.pone.0009126
[37]
Wauquier N, Becquart P, Gasquet C, Leroy EM (2009) Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg Infect Dis 15: 1136–1137. doi: 10.3201/eid1507.090402
[38]
Wilson JA, Hevey M, Bakken R, Guest S, Bray M, et al. (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287: 1664–1666. doi: 10.1126/science.287.5458.1664
[39]
Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, et al. (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73: 6024–6030.
[40]
Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y (2007) Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 25: 993–999. doi: 10.1016/j.vaccine.2006.09.076
[41]
Takada A, Ebihara H, Feldmann H, Geisbert TW, Kawaoka Y (2007) Epitopes required for antibody-dependent enhancement of Ebola virus infection. J Infect Dis 196: Suppl 2S347–356. doi: 10.1086/520581
[42]
Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, et al. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401: 228–235. doi: 10.1016/j.virol.2010.02.029
[43]
Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786–790. doi: 10.1038/nm1258
